Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance - Wikidata - awgldk - TriplyDB

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

http://www.wikidata.org/entity/Q24669898

about

Prevalence of monoclonal gammopathy of undetermined significance: a systematic review Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma Appraisal of immunoglobulin free light chain as a marker of response Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system Prevention of progression in monoclonal gammopathy of undetermined significance High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis Immunoglobulin free light chains and solitary plasmacytoma of bone Does my patient with a serum monoclonal spike have multiple myeloma?Smoldering multiple myeloma requiring treatment: time for a new definition?Characterization of monoclonal gammopathy in patients with amyotrophic lateral sclerosis.Data quality of the monoclonal gammopathy of undetermined significance diagnosis in a hospital registry.Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) magnetic resonance imaging as a biomarker for symptomatic multiple myeloma.Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature.Assessment of free light chains in the cerebrospinal fluid of patients with lymphomatous meningitis - a pilot study Immunophenotypic studies of monoclonal gammopathy of undetermined significance Lymphoproliferative disease-related mixed cryoglobulinemia treated with rituximab and prednisolone Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations.Association between abnormal serum free light chains ratio and known prognostic factors in lymphoma; a nephrology viewpoint.The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.Circulating serum free light chains as predictive markers of AIDS-related lymphoma.Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey.Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study Initial survival data of kidney transplant patients with pre-transplant monoclonal gammopathy.Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications.Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms.Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study.Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy Myelomagenesis: capturing early microenvironment changes Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.Diagnosis and management of neuropathies associated with plasma cell dyscrasias.Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study.85-year-old man with epistaxis

P2860

Q24597406-247A6639-BA08-4631-8F47-A7C154ADB6F3 Q24607241-A2913FD9-EFF4-45EC-B14A-ECC48910F456 Q24619589-FA72A664-3956-4FF7-B0E7-1BF0AED4135C Q24624398-274260E8-52A2-48CA-A403-3AF2533A8D67 Q24647620-12FAC868-AABF-4E39-A698-4088EC5F1AF8 Q24650785-EC07B443-7C71-471A-9BB0-08069CBF2A20 Q24653006-1D24D128-F301-4DF5-AF1E-C13FCD884A49 Q24653434-F49A9C46-071C-480B-96DD-2A1259E2ADC2 Q24655581-9AF89A86-138B-48C9-8DCE-535BEBF447EE Q24670135-B131FB45-DCE1-4D55-A59E-7AE3BDAEA482 Q24685868-26235BF4-F923-4267-9E3F-6FF623C13EB9 Q26821981-F7A8E743-BE02-47CC-8AB5-DD96D6140DC3 Q26996579-7FFB2296-DD0C-4AF8-BE5A-D98E65BCFDAA Q30316799-C86E0664-AF1E-44A3-90C8-B64382CE8F87 Q30665280-CC44DB74-56D7-458D-9101-F23208528B74 Q30897960-3B6DBB09-5BC9-45D1-A406-40BA74DC1B8F Q31146661-BB946AFE-207B-4D30-B112-C02230214B95 Q33301492-2DEBB198-91E1-46BE-A452-1EF2FA5546AF Q33387979-EB4853DD-568A-4B20-88D9-E317FDF7E502 Q33628235-C3CD744F-200B-4664-B9C5-CA8BAD586A61 Q33628815-D5FFF084-1991-4CBD-8105-3985B56D95B1 Q33652326-B2D82DB0-F819-4F58-A0EF-684377D10223 Q33695919-3D6948F8-FEF4-4A74-9F79-E05D2696B554 Q33710567-2FBC6AA2-C250-4107-9620-1B9EE27C1262 Q33875675-EC560492-438B-4F5E-B5F7-C6D2F1A87049 Q33997173-9A50492F-9162-408C-8317-951B69257BFD Q34063865-3174E053-37CF-4A1C-B65C-571D05B1832A Q34184698-E701BC2D-5445-4DF7-A217-B228FC240C5D Q34256144-144935D2-BDD5-4594-BD08-8DDAEF7E68BD Q34316559-4AF58D03-8906-4E69-AEE5-4207EE494E72 Q34316858-04E32867-D79E-4C72-ACCB-3CE6429FEA24 Q34370957-53DA3ECF-3AF3-4C7C-BFC3-5A94BECC57C8 Q34519296-5228137D-3D1E-4117-BDF6-DFDC06F1A5AB Q34525834-BC8B68EA-942D-49F2-8975-690C13F1351C Q34555067-BB627301-8349-47EA-B37E-5E3975F175A3 Q34556156-2328FED7-492A-422A-A007-A2A7A83340C2 Q34580260-56BAFC10-83C1-44B6-B3C3-9305809D4762 Q34615704-FB51743B-1AB4-44AC-BC3A-D3E7B1F09E3C Q34637209-D1D4B9FD-9CAA-4861-A49B-4B71AE5BC42F Q34748502-418C016F-EAC0-448E-A425-34BD3B47D579

P2860

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

http://www.wikidata.org/entity/Q24669898

description

2005 nî lūn-bûn

@nan

2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Serum free light chain ratio i ...... y of undetermined significance

@ast

Serum free light chain ratio i ...... y of undetermined significance

@en

Serum free light chain ratio i ...... y of undetermined significance

@nl

type

label

Serum free light chain ratio i ...... y of undetermined significance

@ast

Serum free light chain ratio i ...... y of undetermined significance

@en

Serum free light chain ratio i ...... y of undetermined significance

@nl

prefLabel

Serum free light chain ratio i ...... y of undetermined significance

@ast

Serum free light chain ratio i ...... y of undetermined significance

@en

Serum free light chain ratio i ...... y of undetermined significance

@nl

P1433

Q24669898-43916DE0-B755-448C-B8CE-1BD9D31217D9

P1476

Q24669898-DEBDA6E1-FA35-403D-B349-8B4F8DEDFFF4

P2093

Q24669898-7E624FF6-25B1-4A60-8532-23F3D7C5D00C

Q24669898-88CAA2A2-3645-49BC-AA7C-08202191E91E

Q24669898-927E9096-24E4-4077-AEA8-87DA9E4AAB60

Q24669898-9FFC281F-07CF-467F-9A87-7535B7BA6C28

Q24669898-A974AE65-1A24-4D2F-ABEC-C78C5B3C18E1

Q24669898-F2F1FF50-9447-449A-A989-D4C049E59998

P2860

Q24669898-0D76771F-00A8-4374-B1E0-3FE82F7840A6

Q24669898-2898C2DB-590F-4809-B55A-BAE08F77FFA3

Q24669898-3D49CE1D-E2DC-447F-BA85-D7969BAB6376

Q24669898-5A4D9794-3B7E-4DF8-955A-817FFFE75106

Q24669898-7191102E-1C2E-4018-8D66-DED529097CB9

Q24669898-868B19D9-79FA-4F4A-B80D-DC0577873829

Q24669898-8BF7D05D-6F15-493A-ACF1-10E35977F1E3

Q24669898-8CF13899-70A0-4345-9CA2-68109A7C2C40

Q24669898-8FBD7DDD-5442-4915-8089-114D76684835

Q24669898-96CD53B1-E193-42DA-8801-9C1BC60CC3F6

P304

Q24669898-77B52BBF-09EC-4E6B-9450-6672DD283A9D

P31

Q24669898-4C99B80E-662C-4C4D-A5E1-76293542151A

P356

Q24669898-BCC15B4D-234B-4204-A5D3-E67703322B09

P407

Q24669898-F5E0C37C-9303-4F2E-86B9-36AB4F88E801

P433

Q24669898-89D4CED1-269D-4AC1-AEFC-F1E6532F51F6

P478

Q24669898-8EE78FBF-AD45-4A46-A6BD-183425A93A53

P50

Q24669898-1C2AEB09-78C0-42DE-9412-C0C890BD265A

Q24669898-86E3446A-8796-4A98-8708-20BA77100B95

Q24669898-97B7438B-24A5-47F2-8EBF-F1C22399E60B

Q24669898-D5F2E2E2-051A-436D-9AFE-79B820BB6881

P577

Q24669898-EE8EF9DA-E74D-4582-B314-F3C63D386B29

P5875

Q24669898-3968A558-AB43-4E2E-B6E1-8A62DBC4C318

P698

Q24669898-0C5190A3-FF88-4C2B-B8FE-3AC8AD814F11

P921

Q24669898-6386BF55-28C4-41DD-A586-6990975982A2

Q24669898-C58D1CAE-4D9D-4227-8B1C-5AF3993E30BC

P932

Q24669898-B43976AF-E2CB-4F16-816B-5538D911FBE6

P356

BLOOD-2005-03-1038

P1433

P1476

Serum free light chain ratio i ...... y of undetermined significance

@en

P2093

Dirk R Larson

http://www.w3.org/2001/XMLSchema#string

Jerry A Katzmann

http://www.w3.org/2001/XMLSchema#string

L Joseph Melton

http://www.w3.org/2001/XMLSchema#string

Matthew F Plevak

http://www.w3.org/2001/XMLSchema#string

Raynell J Clark

http://www.w3.org/2001/XMLSchema#string

Terry M Therneau

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains

Thalidomide for previously untreated indolent or smoldering multiple myeloma.

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Monoclonal gammopathies of undetermined significance.

Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma.

Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma.

Serum test for assessment of patients with Bence Jones myeloma.

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.

Multiple myeloma.

P304

812-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-03-1038

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Angela Dispenzieri

Arthur R Bradwell

S. Vincent Rajkumar

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7883288

http://www.w3.org/2001/XMLSchema#string

P698

15855274

http://www.w3.org/2001/XMLSchema#string

P921

P932

1895159

http://www.w3.org/2001/XMLSchema#string